Crucell corporate brochure (PDF)

16
Our business – Research and development
HIV (Phase I)
Human immunodeficiency virus (HIV) is a retrovirus that causes acquired
immune deficiency syndrome (AIDS), a condition in which the immune
system progressively fails, leading to life-threatening infections. Over the
past 25 years, HIV infection resulting in AIDS has claimed millions of lives,
devastated communities, and enormously frustrated efforts to fight
poverty, improve global health and promote economic development.
According to the 2010 Progress Report (a joint report by UNAIDS,
Unicef and WHO), the HIV epidemic remains a major global public health
challenge, with a total of 33.4 million people living with HIV worldwide.
In 2008 alone, 2.7 million people were newly infected with HIV.
1 Source: WHO, factsheet on rabies.
www.crucell.com
In August 2010, Crucell announced its participation in an international
Phase I clinical trial in the United States and Africa of a combination
of two AdVac®-based AIDS vaccine candidates, Ad26.ENVA.01 and
Ad35-ENV, in healthy adults who are not infected with HIV. The clinical
trial, which will be led by the International AIDS Vaccine Initiative (IAVI),
represents a collaboration between IAVI, Crucell, the Ragon Institute,
and Beth Israel Deaconess Medical Center (BIDMC), a major teaching
hospital of Harvard Medical School.
In 2008, an estimated 2.7 million people
were newly infected with HIV.
Source: WHO.
Every 17,5 seconds one person dies of AIDS.
Source: Stop Aids Now!
The Ad26.ENVA.01 vaccine candidate used in this study is developed
and manufactured by Crucell, while the Ad35-ENV vaccine is developed
by IAVI. Both vaccines candidates are based on Crucell’s proprietary
AdVac® technology. The planned Phase 1 trial of the vaccine combination
represents a key step towards proof of concept studies to evaluate the
efficacy of the vaccine combination in humans.
HPV (Discovery/Pre-clinical)
Genital infection with human papilloma virus (HPV) is very common in
both men and women and usually spontaneously clears within one year
after infection. In about 1% of individuals, however, HPV persists and
ultimately results in genital neoplastic lesions.